- Home
- HQL vs RIGL Comparison
HQL vs RIGL Comparison
Compare HQL & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQL
- RIGL
- Stock Information
- Founded
- HQL 1992
- RIGL 1996
- Country
- HQL United States
- RIGL United States
- Employees
- HQL N/A
- RIGL N/A
- Industry
- HQL Investment Managers
- RIGL Biotechnology: Pharmaceutical Preparations
- Sector
- HQL Finance
- RIGL Health Care
- Exchange
- HQL Nasdaq
- RIGL Nasdaq
- Market Cap
- HQL 369.6M
- RIGL 335.5M
- IPO Year
- HQL N/A
- RIGL 2000
- Fundamental
- Price
- HQL $12.54
- RIGL $18.93
- Analyst Decision
- HQL
- RIGL Buy
- Analyst Count
- HQL 0
- RIGL 5
- Target Price
- HQL N/A
- RIGL $36.40
- AVG Volume (30 Days)
- HQL 120.9K
- RIGL 186.9K
- Earning Date
- HQL 01-01-0001
- RIGL 08-05-2025
- Dividend Yield
- HQL 11.56%
- RIGL N/A
- EPS Growth
- HQL N/A
- RIGL N/A
- EPS
- HQL 0.79
- RIGL 2.08
- Revenue
- HQL N/A
- RIGL $203,077,000.00
- Revenue This Year
- HQL N/A
- RIGL $14.41
- Revenue Next Year
- HQL N/A
- RIGL $15.97
- P/E Ratio
- HQL $17.08
- RIGL $9.09
- Revenue Growth
- HQL N/A
- RIGL 70.16
- 52 Week Low
- HQL $11.34
- RIGL $7.48
- 52 Week High
- HQL $14.37
- RIGL $29.82
- Technical
- Relative Strength Index (RSI)
- HQL 48.60
- RIGL 41.53
- Support Level
- HQL $12.49
- RIGL $21.04
- Resistance Level
- HQL $13.00
- RIGL $21.51
- Average True Range (ATR)
- HQL 0.21
- RIGL 0.99
- MACD
- HQL -0.02
- RIGL -0.27
- Stochastic Oscillator
- HQL 39.69
- RIGL 2.19
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.